BLUEPRINT GENETICS INC

Blueprint Genetics Inc. specializes in advanced genetic analysis and diagnostic sequencing services, leveraging next-generation sequencing (NGS) technologies to support clinical research and precision medicine initiatives. Their core capabilities include variant interpretation, bioinformatics pipeline development, and genomic data analysis for inherited disease detection, cancer genomics, and rare disorder diagnostics. The company applies rigorous quality control standards and proprietary algorithms to ensure high-confidence variant calling and actionable clinical reporting. Technical expertise spans whole exome and whole genome sequencing, copy number variant detection, and integration of genomic findings into electronic health records. Differentiators include scalable laboratory informatics systems, compliance with CLIA and CAP standards, and a focus on translating complex genomic data into clinically meaningful insights for healthcare providers. Award history is not available to infer specific agency relationships or contract patterns. Consequently, no definitive agency experience can be documented based on provided data. The primary NAICS code 621511 indicates operation within medical and diagnostic laboratories, with a focus on clinical genetic testing services. This places Blueprint Genetics Inc. squarely in the precision diagnostics market, serving hospitals, academic medical centers, and research institutions that require high-complexity genomic testing. The company’s market positioning centers on delivering laboratory-developed tests (LDTs) with robust analytical validation and regulatory adherence. Blueprint Genetics Inc. is structured as a small business under the 2L entity classification and is headquartered in Seattle, Washington. While no federal certifications are listed, the company operates under clinical laboratory accreditation frameworks essential for diagnostic service providers. Its geographic presence is anchored in the Pacific Northwest, with a technical footprint aligned with biotech and life sciences innovation hubs. The firm’s government market positioning remains undefined due to lack of public contract data, but its technical capabilities are well-suited for federal health and research missions requiring genomic diagnostics.